Asia Pacific Autoinjectors Market Size and Forecast (2021

Description

List of Tables

The Asia Pacific Autoinjectors Market is projected to reach US$ 1,995.6 Million by 2034, compared with US$ 646.5 Million in 2025. The market is anticipated to expand at a CAGR of 13.6% from 2026 to 2034.

Executive Summary and Asia Pacific Autoinjectors Market Analysis:

The Asia Pacific (APAC) autoinjectors market is witnessing strong expansion, primarily driven by the rising prevalence of chronic diseases that require injectable medications and increasing awareness of the advantages associated with self-administration. According to the International Diabetes Federation (IDF) Diabetes Atlas 2025, approximately 215 million adults aged 20-79 in the Western Pacific subregion were living with diabetes in 2024, representing an age-standardized prevalence of 12.4%. Nearly half of these cases remained undiagnosed, highlighting the substantial unmet healthcare need across the region. Southeast Asia recorded approximately 107 million adults with diabetes during the same year, affecting around one in ten adults, with India representing a significant portion of this population.

The growing incidence of diabetes is generating greater demand for insulin delivery systems and other injectable therapies that can be administered conveniently at home. At the same time, increasing use of biologic medicines for autoimmune and inflammatory disorders is creating additional opportunities for autoinjector manufacturers. Healthcare systems throughout APAC are placing greater emphasis on patient education, self-care, and home-based treatment, while improvements in reimbursement mechanisms are making self-injection technologies more accessible.

Regulatory developments and product innovation are also contributing to market expansion. Authorities in several countries are working toward more efficient approval processes for advanced medical devices, including connected and safety-enhanced autoinjectors. Rising cases of allergies and autoimmune diseases further support demand for epinephrine and biologic delivery devices. Collectively, the region's growing disease burden, improving healthcare access, supportive regulatory environment, and advancements in patient-centric device design are creating favorable conditions for sustained market growth.

Strategic Insights

Asia Pacific Autoinjectors Market Segmentation Analysis:

By Type, the Asia Pacific Autoinjectors Market is segmented into Disposable Prefilled Syringes and Reusable Prefilled Syringes. The Disposable Prefilled Syringes segment dominated the market in 2025.
By Application, the Asia Pacific Autoinjectors Market is categorized into Cancer, Diabetes, Autoimmune Disease, Infectious Diseases, and Others. The Others segment accounted for the largest share in 2025.
By Distribution Channel, the Asia Pacific Autoinjectors Market is segmented into Hospital Pharmacy, Retail Pharmacy, and Online Channel. The Hospital Pharmacy segment held the leading position in 2025.

Market Report Scope

Asia Pacific Autoinjectors Market Outlook

The expanding pipeline of biologics and biosimilars intended for self-administration represents a significant growth opportunity for the autoinjectors industry. Pharmaceutical companies are increasingly developing therapies that can be administered subcutaneously using convenient delivery devices, allowing patients to manage chronic conditions outside traditional clinical environments.

In 2025, the US Food and Drug Administration (FDA) granted interchangeable status to biosimilar versions of adalimumab, including Yuflyma and Hadlima, when delivered through autoinjector formats. This designation can enable pharmacy-level substitution under applicable requirements and potentially improve access to at-home treatment options for chronic inflammatory diseases such as rheumatoid arthritis and Crohn's disease.

Regulatory activity surrounding biologics with subcutaneous delivery options is also increasing. The FDA's Center for Biologics Evaluation and Research (CBER) continues to evaluate biologics license applications, including products incorporating more convenient delivery approaches. These developments demonstrate growing acceptance of self-administered treatment models and create opportunities for pharmaceutical companies and device manufacturers to collaborate on integrated drug-device combinations.

As more therapies transition from infusion-center administration toward self-injection, demand for easy-to-use autoinjectors is expected to increase. Device manufacturers that work closely with pharmaceutical developers to create ergonomic, reliable, and patient-friendly systems will be well positioned to benefit from this trend. Continued innovation in connected devices, dose monitoring, safety mechanisms, and simplified administration can further accelerate adoption across APAC.

Asia Pacific Autoinjectors Market Country Insights

By country, the Asia Pacific Autoinjectors Market is segmented into China, Japan, India, Australia, South Korea, and Rest of Asia Pacific. China held the largest market share in 2025.

China is the leading autoinjectors market in APAC, supported by its large population, substantial chronic disease burden, expanding healthcare access, and increasing adoption of modern drug-delivery technologies. According to IDF data, approximately 148 million adults aged 20-79 in China were living with diabetes in 2024, corresponding to a prevalence of about 13.8%. The significant number of undiagnosed patients provides considerable scope for expanded screening, diagnosis, and long-term disease management.

As diabetes care continues to develop, demand for insulin delivery technologies and convenient self-administration devices is expected to increase. Government programs supporting chronic disease management and digital healthcare are improving access to treatment while encouraging greater patient participation in ongoing care.

Chinese device manufacturers are also focusing on patient-oriented innovations, including prefilled systems, ergonomic designs, simplified injection mechanisms, and connectivity features that can help patients monitor doses and treatment schedules. Meanwhile, the expanding use of biologic medicines for autoimmune and inflammatory diseases is generating additional demand for self-injection platforms.

The combination of a large addressable patient population, improving healthcare infrastructure, government support for digital health, and rising acceptance of home-based treatment positions China as a major growth center for autoinjectors in the Asia Pacific region.

Asia Pacific Autoinjectors Market Company Profiles

Some of the key players operating in the market include Phillips-Medisize, Gerresheimer AG, West Pharmaceutical Services Inc, Ypsomed Holding AG, Stevanato Group SpA, Becton Dickinson and Co, Owen Mumford Ltd, Haselmeier GmbH, Nemera, and SHL Medical.

These companies are pursuing strategies such as geographic expansion, product development, technological innovation, strategic collaborations, and mergers and acquisitions. Such initiatives are focused on strengthening manufacturing capabilities, introducing advanced self-injection technologies, improving device usability and safety, and expanding market presence to capitalize on the growing demand for autoinjectors across Asia Pacific.

Product Code: TIPRE00043954

1. Executive Summary

1.1 Analyst Market Outlook

2. Global Autoinjectors Market Landscape

2.1 Overview
2.2 Value Chain Analysis
2.3 Supply Chain Analysis
- 2.3.1 List of Manufacturers/Suppliers
- 2.3.2 List of Potential Customers (Upto 50)
2.4 Porter's Five Forces Analysis
2.5 PEST Analysis

3. Competitive Landscape

3.1 Company Benchmarking by Key Players
3.2 Market Share Analysis, 2025 - By Key Players
3.3 Market Concentration

4. Asia Pacific Autoinjectors Market - Key Industry Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Future Trends
4.5 Impact of Drivers and Restraints:

5. Autoinjectors Market - Asia Pacific Analysis

5.1 Asia Pacific Autoinjectors Market Revenue (US$ Million), 2021 - 2034
5.2 Asia Pacific Autoinjectors Market Revenue Forecast and Analysis

6. Asia Pacific Autoinjectors Market Revenue Analysis - by Type

6.1 Asia Pacific Autoinjectors Market Forecast and Analysis by Type
- 6.1.1 Disposable Prefilled Syringes
  - 6.1.1.1 Overview
  - 6.1.1.2 Disposable Prefilled Syringes: Asia Pacific Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 6.1.2 Reusable Prefilled Syringes
  - 6.1.2.1 Overview
  - 6.1.2.2 Reusable Prefilled Syringes: Asia Pacific Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)

7. Asia Pacific Autoinjectors Market Revenue Analysis - by Applications

7.1 Asia Pacific Autoinjectors Market Forecast and Analysis by Applications
- 7.1.1 Cancer
  - 7.1.1.1 Overview
  - 7.1.1.2 Cancer: Asia Pacific Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.2 Diabetes
  - 7.1.2.1 Overview
  - 7.1.2.2 Diabetes: Asia Pacific Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.3 Autoimmune Disease
  - 7.1.3.1 Overview
  - 7.1.3.2 Autoimmune Disease: Asia Pacific Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.4 Infectious Diseases
  - 7.1.4.1 Overview
  - 7.1.4.2 Infectious Diseases: Asia Pacific Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 7.1.5 Others
  - 7.1.5.1 Overview
  - 7.1.5.2 Others: Asia Pacific Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)

8. Asia Pacific Autoinjectors Market Revenue Analysis - by Distribution Channel

8.1 Asia Pacific Autoinjectors Market Forecast and Analysis by Distribution Channel
- 8.1.1 Hospital Pharmacy
  - 8.1.1.1 Overview
  - 8.1.1.2 Hospital Pharmacy: Asia Pacific Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 8.1.2 Retail Pharmacy
  - 8.1.2.1 Overview
  - 8.1.2.2 Retail Pharmacy: Asia Pacific Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
- 8.1.3 Online Channel
  - 8.1.3.1 Overview
  - 8.1.3.2 Online Channel: Asia Pacific Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)

9. Asia Pacific Autoinjectors Market - Country Analysis

9.1 Asia Pacific
- 9.1.1 Asia Pacific Autoinjectors Market Forecast and Analysis - by Country
  - 9.1.1.1 China Market
    - 9.1.1.1.1 China: Asia Pacific Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
    - 9.1.1.1.2 China: Asia Pacific Autoinjectors Market - By Segmentation
      - 9.1.1.1.2.1 Type
      - 9.1.1.1.2.2 Applications
      - 9.1.1.1.2.3 Distribution Channel
  - 9.1.1.2 Japan Market
    - 9.1.1.2.1 Japan: Asia Pacific Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
    - 9.1.1.2.2 Japan: Asia Pacific Autoinjectors Market - By Segmentation
      - 9.1.1.2.2.1 Type
      - 9.1.1.2.2.2 Applications
      - 9.1.1.2.2.3 Distribution Channel
  - 9.1.1.3 India Market
    - 9.1.1.3.1 India: Asia Pacific Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
    - 9.1.1.3.2 India: Asia Pacific Autoinjectors Market - By Segmentation
      - 9.1.1.3.2.1 Type
      - 9.1.1.3.2.2 Applications
      - 9.1.1.3.2.3 Distribution Channel
  - 9.1.1.4 Australia Market
    - 9.1.1.4.1 Australia: Asia Pacific Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
    - 9.1.1.4.2 Australia: Asia Pacific Autoinjectors Market - By Segmentation
      - 9.1.1.4.2.1 Type
      - 9.1.1.4.2.2 Applications
      - 9.1.1.4.2.3 Distribution Channel
  - 9.1.1.5 South Korea Market
    - 9.1.1.5.1 South Korea: Asia Pacific Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
    - 9.1.1.5.2 South Korea: Asia Pacific Autoinjectors Market - By Segmentation
      - 9.1.1.5.2.1 Type
      - 9.1.1.5.2.2 Applications
      - 9.1.1.5.2.3 Distribution Channel
  - 9.1.1.6 Rest of Asia Pacific Market
    - 9.1.1.6.1 Rest of Asia Pacific: Asia Pacific Autoinjectors Market - Revenue and Forecast, 2021 - 2034 (US$ Million)
    - 9.1.1.6.2 Rest of Asia Pacific: Asia Pacific Autoinjectors Market - By Segmentation
      - 9.1.1.6.2.1 Type
      - 9.1.1.6.2.2 Applications
      - 9.1.1.6.2.3 Distribution Channel

10 Autoinjectors Market Industry Landscape

11 - Key Company Profiles

11.1 Phillips-Medisize
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Gerresheimer AG
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 West Pharmaceutical Services Inc
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Ypsomed Holding AG
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Stevanato Group SpA
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Becton Dickinson and Co
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Owen Mumford Ltd
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Haselmeier GmbH
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 Nemera
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments
11.10 SHL Medical
- 11.10.1 Key Facts
- 11.10.2 Business Description
- 11.10.3 Products and Services
- 11.10.4 Financial Overview
- 11.10.5 SWOT Analysis
- 11.10.6 Key Developments

12. Appendix

12.1 Glossary
12.2 Research Methodology and Approach
- 12.2.1 Secondary Research
- 12.2.2 Primary Research
- 12.2.3 Market Estimation Approach
  - 12.2.3.1 Supply Side Analysis
  - 12.2.3.2 Demand Side Analysis
- 12.2.4 Research Assumptions and Limitations
- 12.2.5 Currency Conversion
12.3 About The Insight Partners
12.4 Market Intelligence Cloud